0001654954-22-011091.txt : 20220811 0001654954-22-011091.hdr.sgml : 20220811 20220811204656 ACCESSION NUMBER: 0001654954-22-011091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220809 FILED AS OF DATE: 20220811 DATE AS OF CHANGE: 20220811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AINOS INC CENTRAL INDEX KEY: 0001859309 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 221157511 BUSINESS ADDRESS: STREET 1: 8880 RIO SAN DIEGO DRIVE STREET 2: SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 213005220 MAIL ADDRESS: STREET 1: 8880 RIO SAN DIEGO DRIVE STREET 2: SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2022-08-09 0001014763 Ainos, Inc. AIMD 0001859309 AINOS INC 14F., NO. 61, SEC. 4 NEW TAIPEI BOULEVARD, XINZHUANG DISTRICT NEW TAIPEI CITY F5 242 TAIWAN true COMMON STOCK 2022-08-09 4 A false 7647058 3.40 A 12311763 D COMMON STOCK 2022-08-09 4 A false 1014319 .20 A 13326082 D Prior to the Reverse Split discussed herein the Reporting Person beneficially owned 69,970,571 common stock of the Issuer and after the Reverse Split, and prior to the present issuances, 4,664,705 common stock. The amounts of securities beneficially owned in column 5 of this report is calculated from a post-split baseline of 4,664,705. Reference is made to that certain non-interest bearing Convertible Note in the principal amount of $26,000,000 issued to the Reporting Person as consideration under an Asset Purchase Agreement with the Issuer ("APA Note"). The APA Note is payable by January 30, 2027 unless converted immediately prior to the closing of a public offering and listing on a U.S. stock exchange at 80% of the initial public offering price ("Offering"). On 08/11/22, the Company completed a public offering at a $4.25 per unit price ("Offering") and a 15-for-1 reverse stock split on 08/08/22 ("Reverse Split"). Transaction reflects an acquisition price of $3.40 per share (80% of the Offering) and the issued shares give effect to the Reverse Split. Reference is made to that certain Convertible Note in the principal amount of $3,000,000 bearing 1.85% interest per annum payable on February 28, 2023 and issued to the Reporting Person as consideration for working capital advances made to the Issuer ("Capital Note"). As of the conversion date, the Capital Note accrued $42,959 in interest and was converted at a $0.20 conversion rate pursuant to the Capital Note. The transaction gives effect to the Reverse Split noted in Footnote 1 above. /s/ John Junyong Lee POA for Chun-Hsien Tsai, Chief Executive Officer 2022-08-11